Healthcare Capital Raises and Syndication

Healthcare capital must respect licensing conditions, clinical risk, and payor behaviour in a way general corporate capital does not. Term sheets, covenants, and security packages need to align with patient safety obligations, clinical staffing, and data rules. We embed these constraints into structure and documentation so investors, lenders, and boards operate with clarity. The result is capital that can be deployed without triggering regulatory or operational instability.

We execute for hospitals, polyclinics, day surgery centers, laboratories, imaging and diagnostics platforms, pharma and device distribution, long-term care, and healthtech, including telemedicine and digital health records. Each vertical carries a different regulatory and reimbursement profile, and we treat that as core to the raise architecture. The mandate is always to align capital to the underlying clinical and commercial model. Structure follows regulatory and operational reality, not the other way around.

We design syndications with clear governance hierarchies, decision rights, and veto thresholds, anchored in the specific risks of the healthcare asset. Inter-investor arrangements are drafted to prevent deadlock on critical matters such as licensing breaches, clinical incidents, or major capex. Information rights, reporting packs, and KPI definitions are standardised across the syndicate. This creates one decision framework, not competing investor agendas.

UAE healthcare regulation defines who can own, operate, and make key decisions within a healthcare entity, and under what conditions. We translate licensing, clinical governance, and data protection rules into shareholder agreements, reserved matters, and management contracts. Where foreign ownership or professional requirements apply, we structure compliant vehicles and contractual frameworks. The objective is regulatory defensibility with no ambiguity on control or accountability.

Yes, we structure blended capital stacks that combine senior debt, mezzanine, and equity while maintaining clinical and regulatory stability. Intercreditor agreements are engineered so that enforcement pathways do not jeopardise licensing or continuity of care. Cash-flow sweeps, covenants, and security packages are calibrated to reimbursement cycles and asset profiles. Equity documentation is aligned so that all stakeholders understand the waterfall and control mechanics.